At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 62 enrolled
Drug / intervention
Tanezumab +1 moredrug
Likely dose
Tanezumab 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 2, 16 WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED, PARALLEL GROUP PROOF-OF-CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF PAIN ASSOCIATED WITH CHRONIC ABACTERIAL PROSTATITIS
In Brief
A Phase 2 clinical trial evaluating Tanezumab and Placebo for Chronic Prostatitis With Chronic Pelvic Pain Syndrome. Completed, enrolled 62 participants across 44 sites in 5 countries.
Detailed Summary
The purpose of this study is to determine whether tanezumab is effective in the treatment of pain associated with chronic prostatitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, France, Sweden, Switzerland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2009
Enrollment StartMar 2009
Primary CompletionJan 2010
Study CompletionMar 2010
TodayJul 2026
First PostedJan 22, 2009
Enrollment StartMar 25, 2009
Primary CompletionJan 11, 2010
Study CompletionMar 17, 2010
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 17.4 years ago
Interventions
Tanezumabdrug
Intravenous, 20 mg, single dose.
Placebodrug
Intravenous placebo, single dose